NCT05809869 is a Phase 2 clinical trial of Durvalumab in Hepatocellular Carcinoma, sponsored by The University of Hong Kong.

Who is sponsoring NCT05809869?

NCT05809869 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT05809869?

Interventions in NCT05809869: Durvalumab, Tremelimumab, Yttrium-90 radioembolisation.

What condition does NCT05809869 study?

NCT05809869 studies Hepatocellular Carcinoma.

Is NCT05809869 still recruiting?

NCT05809869 is currently recruiting now. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT05809869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Recruiting now Phase 2 Last updated 12 April 2023

What this trial tests

Phase 2 trial testing Durvalumab in Hepatocellular Carcinoma in 25 participants. Currently enrolling.

Timeline

15 February 2023

Primary endpoint
31 December 2025

30 June 2026

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	15 February 2023
Primary completion	31 December 2025
Estimated completion	30 June 2026
Sites	1 location across Hong Kong

Drugs / interventions tested

Durvalumab — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →
Yttrium-90 radioembolisation

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatocellular carcinoma is one of the most intractable primary malignancies in the hepatobiliary and pancreatic tract with a poor overall survival worldwide. Unfortunately, the vast majority of hepatocellular carcinoma patients suffer from advanced unresectable or metastatic disease at diagnosis. Currently targeted therapy alone, or in combination with anti-vascular endothelial growth factor antagonist, is the standard first-line treatment for metastatic hepatocellular carcinoma. On the other hand, there is growing evidence suggesting that radiation therapy (external or internal) with or without immune checkpoint inhibitors can produce or even augment abscopal effect in which the tumours away from the radiation field also show significant tumour shrinkage. The underlying mechanism of eliciting abscopal effect includes the increased antigen presentation by the myeloid cells within the tumour stroma leading to enhanced tumour cell killing. Previous case reports showed that radiation therapy alone can induce abscopal effect in mice and human models. However, a robust and concrete evidence of abscopal effect with combinational immune checkpoint inhibitors and radioembolisation or external radiation therapy in hepatocellular carcinoma is still lacking. This study investigates the efficacy and safety of immune checkpoint inhibitors and radioembolisation as first-line treatment for previously untreated metastatic hepatocellular carcinoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
Chan YT, Zhang C, Wu J, Lu P, et al · · 2024 · cited 158× · PMID 39242496 · DOI 10.1186/s12943-024-02101-z
Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.
Villalobos A, Dabbous HH, Little O, Gbolahan OB, et al · · 2023 · cited 14× · PMID 38132368 · DOI 10.3390/curroncol30120734
Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips.
Villalobos A, Pisanie JLD, Gandhi RT, Kokabi N. · · 2024 · cited 6× · PMID 38495257 · DOI 10.1055/s-0044-1779715
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma.
Tojjari A, Yu J, Saeed A. · · 2024 · cited 5× · PMID 38473415 · DOI 10.3390/cancers16051058
Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review).
Ma C, Yu X, Zhang X, Su L, et al · · 2025 · cited 4× · PMID 40438865 · DOI 10.3892/ol.2025.15088
Efficacy and safety of the immune checkpoint inhibitor-radiotherapy combination in advanced/unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Cui R, Yu X, Jiang Y, Li X. · · 2025 · cited 2× · PMID 40776902 · DOI 10.3892/ol.2025.15206
Concurrent Radiation and Immunotherapy for Unresectable Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombus.
Krishnamurthy N, Cherry D, Rodriguez-Russo C, Buckstein M. · · 2025 · PMID 40837214 · DOI 10.1016/j.adro.2025.101856

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05809869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing